Eyepoint Pharmaceuticals Stock Today
| EYPT Stock | USD 6.25 0.15 2.46% |
PerformanceVery Weak
| Odds Of DistressLow
|
Eyepoint Pharmaceuticals is selling for under 6.25 as of the 23rd of March 2025; that is 2.46 percent increase since the beginning of the trading day. The stock's last reported lowest price was 5.93. Eyepoint Pharmaceuticals has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 23rd of December 2024 and ending today, the 23rd of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 27th of January 2005 | Category Healthcare | Classification Health Care |
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts. The company has 68.73 M outstanding shares of which 11.09 M shares are currently shorted by private and institutional investors with about 11.92 trading days to cover. More on Eyepoint Pharmaceuticals
Moving together with Eyepoint Stock
Moving against Eyepoint Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Eyepoint Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Nancy Lurker | ||||
| Thematic Idea | Measuring and Control Equipment (View all Themes) | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Measuring and Control Equipment, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsEyepoint Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Eyepoint Pharmaceuticals' financial leverage. It provides some insight into what part of Eyepoint Pharmaceuticals' total assets is financed by creditors.
| |||||
Eyepoint Pharmaceuticals (EYPT) is traded on NASDAQ Exchange in USA. It is located in 480 Pleasant Street, Watertown, MA, United States, 02472 and employs 165 people. Eyepoint Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 429.56 M. Eyepoint Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 68.73 M outstanding shares of which 11.09 M shares are currently shorted by private and institutional investors with about 11.92 trading days to cover.
Eyepoint Pharmaceuticals currently holds about 171.17 M in cash with (126.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.02.
Check Eyepoint Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationThe majority of Eyepoint Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Eyepoint Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Eyepoint Pharmaceuticals. Please pay attention to any change in the institutional holdings of Eyepoint Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.
Check Eyepoint Ownership Details
Eyepoint Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Goldman Sachs Group Inc | 2024-12-31 | 1.7 M | |
| Geode Capital Management, Llc | 2024-12-31 | 1.5 M | |
| Perceptive Advisors Llc | 2024-12-31 | 1.5 M | |
| State Street Corp | 2024-12-31 | 1.5 M | |
| Patient Square Capital | 2024-12-31 | 1.4 M | |
| Essex Woodlands Health Ventures | 2024-12-31 | 1.2 M | |
| Finepoint Capital Lp | 2024-12-31 | 1.1 M | |
| 5am Venture Management, Llc | 2024-12-31 | 1.1 M | |
| Point72 Asset Management, L.p. | 2024-12-31 | 857.9 K | |
| Cormorant Asset Management, Llc | 2024-12-31 | 8.3 M | |
| Suvretta Capital Management, Llc | 2024-12-31 | 6.8 M |
Eyepoint Pharmaceuticals Historical Income Statement
Eyepoint Stock Against Markets
Eyepoint Pharmaceuticals Corporate Management
| David Jones | Senior Officer | Profile | |
| Jay MD | Chief Officer | Profile | |
| Michael Pine | Chief Officer | Profile | |
| Ramiro MD | Chief Officer | Profile | |
| Jennifer Leonard | Chief IT | Profile |
Additional Tools for Eyepoint Stock Analysis
When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.